Clinical Trial Search

Primary: Change From Baseline on Day 21 in Relative Abundance of CAMP mRNA in Lesional and Non-Lesional Skin for Atopic Dermatitis (AD) Participants Who Received Oral Vitamin D3…

Primary: Response — 0; 0; 8; 2 Participants

Primary: Forced Expiratory Volume in One Second (FEV1) Peak Within 0-3 Hours Post-dose Response — 0.116; 0.255; 0.244; 0.304 Litre — p=<0.0001

Primary: Safety and Tolerability of Caspofungin in Four Escalating Dosages in Adult Patients With Hematologic Malignancies and Proven or Probable Invasive Aspergillosis — 11; 12…

Primary: Reduction in Plasma Uric Acid to Less Than 6 mg/dL. — 17 Participants

Primary: Number of Subjects With Serious Adverse Events (SAEs). — 17; 17 subjects

Primary: 16-month Overall Survival (OS) — 64.8 percentage of participants

Primary: The Number of Men With Advanced Prostate Cancer Treated With Trabectedin Who Have a PSA Response — 7 participants

Primary: The Mean Change From Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1) — 0.039; 0.054; 0.124; 0.166 liters

Primary: Participants' Response in Prostate-Specific Antigen (PSA) Level at Three Months As Compared to Baseline — 16.67; 33.33; 83.33; 66.67 percentage of participants

Primary: 6-month Progression-free Survival — 88.8 percentage of participants

Primary: The Mean Change From Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1) — 0.051; 0.073; 0.076; 0.121 liters

Primary: 24 Week Progression Free Survival — 23 percentage of participants

Primary: Response — 11 participants

Primary: Percent of Patients With Change in Combined Bone Mass Density T-score <= -0.5. — 3.7; 10.5 percentage of patients